Neil M. Iyengar

2 months ago | onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli

OpinionVideoJanuary 29, 2025Author(s):,Panelists discuss how emerging data on HER2-ultralow breast cancer is informing treatment decisions, particularly regarding the potential role of trastuzumab deruxtecan, while acknowledging the need for careful patient selection and consideration of traditional treatment sequences. Video content above is prompted by the following:Briefly discuss how you approach treatment for patients with HER2-ultralow metastatic breast cancer.

2 months ago | onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli

OpinionVideoJanuary 29, 2025Author(s):,Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations. Video content above is prompted by the following:Please discuss the recent findings from the DESTINY-Breast06 trial, highlighting key efficacy and safety findings and their implications for the treatment of HER2-low/ultralow metastatic breast cancer.

Jan 22, 2025 | onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli

OpinionVideoJanuary 22, 2025Author(s):,Panelists discuss how clinical trials like DESTINY-Breast04, TROPiCS-02, and TROPION-Breast01 have revolutionized treatment options for HER2-low advanced breast cancer by validating novel targeted therapies and antibody-drug conjugates. Video content above is prompted by the following:Provide a brief overview of the treatment landscape for HER2-low advanced breast cancer.

Jan 17, 2025 | oncologynewscentral.com | Arya Roy |Neil M. Iyengar

This interview, recorded during the Oncology Brothers live event, Advancements in Oncology, which coincided with SABCS in San Antonio, features Dr. Arya Mariam Roy (The Ohio State University Comprehensive Cancer Center) interviewing Dr. Neil Iyengar (Memorial Sloan Kettering Cancer Center).

Dec 4, 2024 | cancernetwork.com | Neil M. Iyengar

The field of oncology continues to evolve rapidly, with transformative advances in 2024 offering novel diagnostic and therapeutic options. Below are some of the most impactful advances from 2024, which span various cancer types, therapeutic approaches, and treatment settings. First, we have seen new and improved liquid biopsy assays with high sensitivity for the detection and sequencing of circulating tumor DNA (ctDNA).